Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years

Article English OPEN
Dahl, R; Kapp, A; Colombo, G; De Monchy, JGR; Rak, S; Emminger, W; Riis, B; Gronager, PM; Durham, SR;
(2008)
  • Publisher: MOSBY-ELSEVIER
  • Journal: volume 121, pages 512-518issn: 1085-8725
  • Publisher copyright policies & self-archiving
  • Related identifiers: doi: 10.1016/j.jaci.2007.10.039
  • Subject: Hypersensitivity | tablet based | Desensitization, Immunologic | SEASONAL RHINOCONJUNCTIVITIS | RANDOMIZED CONTROLLED-TRIAL | RHINITIS | Antigens, Plant | rhinoconjunctivitis | FOLLOW-UP | CHILDREN | SAFETY | immunotherapy | Phleum pratense | POLLEN IMMUNOTHERAPY | placebo-controlled | Female | MECHANISMS | double-blind | Double-Blind Method | Poaceae | allergy | ASTHMA | Administration, Sublingual | Middle Aged | Conjunctivitis | Treatment Outcome | grass pollen | UMCG Approved | sublingual | EFFICACY | Follow-Up Studies | Adult | Humans | Tablets | Male

Udgivelsesdato: 2008-Feb BACKGROUND: This is an interim analysis of a randomized, double-blind, placebo-controlled phase III trial with 3 years of daily treatment with grass tablet immunotherapy (GRAZAX; ALK-Abelló A/S, Hørsholm, Denmark) or placebo, followed by 2 ye... View more
Share - Bookmark